Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NBI-5788 Neurocrine.

Cynthia L Darlington1

  • 1Department of Pharmacology and Toxicology, School of Medical Sciences, University of Otago Medical School, Dunedin, New Zealand. cynthia.darlington@stonebow.otago.ac.nz

Current Opinion in Investigational Drugs (London, England : 2000)
|July 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Animal studies linking the vestibular system and memory: Aotearoa/New Zealand's contribution.

Journal of the Royal Society of New Zealand·2025
Same author

Sexual dimorphism in vestibular function and dysfunction.

Journal of neurophysiology·2019
Same author

Video head impulse in comparison to caloric testing in unilateral vestibular schwannoma.

Acta oto-laryngologica·2016
Same author

The Effects of Complete Vestibular Deafferentation on Spatial Memory and the Hippocampus in the Rat: The Dunedin Experience.

Multisensory research·2015
Same author

The effects of acute stress-induced sleep disturbance on acoustic trauma-induced tinnitus in rats.

BioMed research international·2014
Same author

Galvanic vestibular stimulation impairs cell proliferation and neurogenesis in the rat hippocampus but not spatial memory.

Hippocampus·2014

Neurocrine Biosciences is developing NBI-5788, a novel treatment for multiple sclerosis. This myelin basic protein epitope analog is undergoing phase II trials for intravenous administration.

Area of Science:

  • Neuroimmunology
  • Neurology
  • Drug Development

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease targeting the central nervous system.
  • Myelin basic protein (MBP) is a key autoantigen implicated in the pathogenesis of MS.
  • Current MS treatments aim to manage symptoms and reduce disease progression.

Purpose of the Study:

  • To evaluate the safety and efficacy of NBI-5788, an MBP epitope analog, as an intravenous treatment for multiple sclerosis.
  • To assess the immunomodulatory potential of NBI-5788 in patients with MS.

Main Methods:

  • NBI-5788, an analog of an immunodominant epitope of myelin basic protein, was administered intravenously.
  • Phase II clinical trials were conducted to assess the treatment's effects.

Related Experiment Videos

  • Patient enrollment for phase II trials was completed by April 2005.

    • Main Results:

    • Enrollment for phase II trials was completed in April 2005.
    • Results from the phase II trials were anticipated in early 2006.
    • The study focused on the potential therapeutic effects of NBI-5788 in MS patients.

    Conclusions:

    • NBI-5788 represents a potential new therapeutic strategy for multiple sclerosis.
    • Further investigation into the efficacy and safety of NBI-5788 is warranted based on ongoing trial results.